You are here: Industry Insights > CAR-T

News List

Refuge Biotech scores $25M from Chinese backers for 'intelligent' CAR-T fiercebiotech
May 03, 2018
3SBio and Sequioa China led Refuge Biotechnologies' $25 million series B, which will advance the Bay Area biotech's dead Cas9-based cell therapies.
CAR-T 2.0? A split, universal and programmable system fiercebiotech
April 27, 2018
Recent FDA approvals have validated the use of chimeric antigen receptor T cells (CAR-Ts) to fight blood cancers...
CAR-T Trailblazer Carl June Who Collaborated on Novartis’ Kymriah Makes Time's 100 Influential List biospace
April 24, 2018
A pioneer in CAR-T therapies has been named one of Time Magazine’s 100 most influential people in the world for 2018.
Cellectis Snags $164 Million in IPO to Advance CAR-T Programs biospace
April 12, 2018
During the J.P. Morgan Healthcare Conference Andre Choulika, chief executive officer of France-based Cellectis told BioSpace he was excited about the future of CAR-T therapiesand where his company fits into the space.
The 7th Enterprise Applying for CAR-T in China: What are the Advantages of Unicar? Dopine
February 26, 2018
2017 was an important node in the development of CAR T-cell immunotherapy, where the two cell immunotherapies of Novartis and Gilead were successively approved by FDA.
Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017 fiercebiotech
January 23, 2018
Celgene has agreed to buy CAR-T specialist Juno Therapeutics for around $9 billion in a deal that instantly makes it a big cheese in this emerging therapeutic category.
2018: Gilead is Not Done Shopping biospace
January 11, 2018
One of last year’s big stories was Gilead Sciences acquiring Kite Pharma for about $11.9 billion in late August.
Janssen Forges Global Pact With Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy biospace
December 25, 2017
Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy
Gilead makes $567m strategic acquisition for next-gen CAR-T pharmafile
December 11, 2017
It’s only four months since Gilead completed its buy-out of Kite Pharma for $11.9 billion, but it’s already moving quickly to establish bolt-on technology to take its CAR-T therapy forward.
Promising new CAR-T therapy able to target T-cell lymphoma pharmafile
November 16, 2017
The CAR-T space has progressed rapidly over the last few years, culminating in FDA approvals for Novartis and Gilead to treat B-cell lymphomas; however...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page